Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certican add-on therapy against cytomegalovirus disease in renal transplant patients
2008-004745-28Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in cytomegalovirus disease (CMV) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Lowering of CMV titers. Started Aug 2008; status: completed.
02
Drugs
everolimus
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2008-004745-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004745-28.